Pneumonia continues to be an important cause of mortality in under-five children [1] . There has been considerable interest in use of Vitamin D in preventing childhood pneumonia and in improving the outcomes of children with pneumonia. Vitamin D, a fat-soluble vitamin, apart from calcium and phosphate homeostasis, has multiple effects. It modulates innate and acquired immunity and regulates inflammatory cascade. Many of the immune cells express Vitamin D receptors. Vitamin D regulates macrophage and dendritic cell activities and toll like receptor mediated response in neutrophils. Vitamin D induces expression of cathelicidin and β-defensin which have chemotactic and toxin neutralization properties [2] . Association between Vitamin D deficiency and increased risk of pneumonia is well studied [3, 4] . Also, association between Vitamin D deficiency and severity of lower respiratory tract infection has been recognized [5] . However, these associations and possible biologic basis for role of preventing and improving treatment outcomes of childhood pneumonia have not been supported by clinical trials.
Yakoob et al., evaluating the role of Vitamin D in preventing infections in their systematic review, included two trials on childhood pneumonia and found that there was no difference in the incidence of first episode of pneumonia in children supplemented with Vitamin D [6] . For use of Vitamin D as an adjunct to antibiotic treatment of childhood pneumonia, Das et al. in their systematic review reported that the effects of Vitamin D supplementation in childhood pneumonia on outcomes, including time to resolution of acute illness, mortality rate and resolution of fever, were inconclusive and the quality of evidence was low to very low [7] .
Some children with pneumonia may be at risk of recurrence of pneumonia. Researchers have also evaluated the role of Vitamin D in reducing this risk of recurrence.
In the current issue, Singh et al. report the results of randomized controlled trial evaluating the role of Vitamin D supplementation of 3,00,000 IU quarterly doses for 4 doses in the prevention of recurrence of pneumonia in under-five children and reported no statistically significant beneficial effect [8] . The mean lower respiratory tract infection (LRTI) episodes were slightly less in the intervention group, although the mean duration of LRTI episodes was longer in the intervention group. Also, they observed no benefit in the mean upper respiratory tract infection (URTI) episodes, complication rate and severity of pneumonia. The follow up period was sufficiently long. But the study has few limitations. It was from a small cohort of children (the sample size calculation was not provided). Also, as mentioned by the authors, follow up Vitamin D levels were not available [8] .
In a similar community-based study done in Kabul enrolling 3046 children, Vitamin D was administered to young infants quarterly at a dose of 1,00,000 IU; there was no difference in incidence of first or only episode of pneumonia although incidence of repeated episodes of pneumonia was higher in the Vitamin D group [9] . Gupta et al., in a doubleblind randomized trial found that Vitamin D supplementation did not reduce the risk of recurrence of pneumonia in 6-mo follow up period [10] .
While there have been differences in the dosing schedules of different studies, current evidence does not support the use of Vitamin D in prevention or treatment of childhood pneumonia; neither the immediate outcomes nor the risk of recurrence of pneumonia seem to benefit from Vitamin D supplementation.
